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This issue of the Journal features an experimental study on
the triad of hypertrophy, ischemia and reperfusion (1). The
results offer the promise that a targeted pharmacologic
intervention may improve metabolism and function of the
postischemic heart. Although this is not a completely novel
concept, the link between energy substrate metabolism and
function of the reperfused heart is not always appreciated.
The importance of these findings is therefore better appre-
ciated when viewed in a broader context.
See page 1378
Although metabolism of fuels provides the heart with the
energy required for contraction, a discussion of myocardial
energy substrate metabolism has all but disappeared from
textbooks of cardiology. In the 1970s, when I was a
cardiology fellow at the Peter Bent Brigham Hospital in
Boston, case presentations used to end with the phrase
“coronary sinus lactate levels are pending,” an oblique
reference to the hypothesis that small-vessel coronary artery
disease can be detected by a rise in sinus lactate levels due to
a shift from aerobic to anaerobic glucose metabolism (2).
The clinical usefulness of these measurements, however,
never materialized. Over the years, metabolism became a
lost child of cardiology.
Almost concurrently, the study of cardiac metabolism
evolved into an attractive discipline to biochemists and
physiologists who saw in the heart an ideal model system for
the examination of metabolism and function of an intact
organ (quite literally, a conveniently packaged bag of en-
zymes). The understanding of metabolic regulation at a
cellular level advanced rapidly in the 1960s and 1970s (3).
By using a strictly reductionist approach, a system of
enormous complexity was unraveled. Indeed, a general
approach at that time included reducing metabolism and
function to molecular science, identifying and purifying the
relevant molecules and finding activators or inhibitors which
they bound.
Two major advances in technology brought the intact
heart back into focus: In the 1980s, nuclear magnetic
resonance spectroscopy revitalized the field of bioenergetics
(4,5), and positron emission tomography delivered the
promise of regional assessment of metabolic activity (6).
However, the results obtained with these new techniques
were largely predictable. Despite the undisputed clinical
usefulness, few truly new paradigms emerged from this
work.
Energy transfer in the heart. Because the whole is greater
than the sum of its parts, an understanding of the control
and regulation of energy substrate metabolism remains an
important field of research. Energy is the capacity to do
work. The release of energy from fuels is achieved by the
step-by-step processes of enzymatically controlled fuel me-
tabolism and mitochondrial oxidative phosphorylation, in
which the energy content of fuels is transferred to the high
energy phosphate bonds of adenosine triphosphate (ATP).
Metabolism and contraction of the heart are therefore
inseparably linked, which means that ATP must be contin-
uously remade by the dynamo of metabolism. The high
turnover rate of ATP means that energy passes through it
for all but a fleeting moment. As a result, there is also no
correlation between ATP content and ATP turnover in the
normal or reperfused heart (5,7).
The first law of thermodynamics is that energy cannot be
created or destroyed by any process. It can only be converted
from one form into another form. In the heart, like in all
cells of the body, efficient energy transfer arises from the
interaction of a series of moiety conserved cycles (3). The
cell’s key task is to match rates of ATP production to rates
of ATP consumption; this is made difficult because the
primary site of ATP production (mitochondria) is separate
from the primary site of ATP utilization (sarcomeres). The
mechanism by which the precise matching between ATP
production and utilization occurs is presently unknown. We
can say with certainty, however, that “all is in flux.”
Which fuel? The heart is a metabolic omnivore and is able
to meet its need for energy from the oxidation of fatty acids,
glucose, lactate and other oxidizable substrates. Studies in
the isolated working rat heart, where substrate concentra-
tions can be precisely controlled, have shown that fatty acids
inhibit glucose oxidation to a greater extent than glucose
inhibits fatty acid oxidation, and that the heart functions
best when it oxidizes the two substrates simultaneously (8).
This principle is appropriately illustrated by the develop-
ment of hypertrophy and failure in tissue-specific knock-out
models of enzymes of glucose (9) or fatty acid metabolism
(10) and by the recently described lipotoxic heart disease in
obese rats (11).
Metabolism of glucose to lactate is the main source of
energy for the ischemic heart. When lack of oxygen induces
a shift from aerobic to anaerobic metabolism, there is rapid
stimulation of glucose uptake, glycogenolysis, glycolytic flux
and ATP hydrolysis (12). Such an increase in glycolysis is
also observed in hypertrophied hearts perfused with low
concentrations of fatty acids (13) and is consistent with an
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increase in glycolytic enzyme activities (14). Despite this
increase in glycolysis, rates of glucose oxidation are de-
creased in hypertrophied as compared with normal hearts,
resulting in a greater amount of pyruvate converted to
lactate and in an uncoupling of glycolysis from glucose
oxidation (13). Hydrolysis of two ATPs for each molecule
of glucose metabolized to lactate (and not oxidized) pro-
duces two hydrogen ions (H1) (15). Acidosis is implicated
in contractile dysfunction of the heart (16,17). The excess
production of H1 may contribute to impaired function of
the failing heart.
In the isolated working rat heart, brief periods of isch-
emia (up to 20 min) result in a dissociation between the
early return of oxidative metabolism and a delayed return of
contractile function (18). Although it has long been appre-
ciated that fatty acids decrease cardiac efficiency (19,20), the
main reason for contractile dysfunction is thought to be the
delayed clearance of protons from the cell. One hypothesis
is that increased glucose oxidation during reperfusion re-
duces the proton load and improves functional recovery
(21,22).
Metabolic adaptations. Ischemia followed by reperfusion,
on the one hand, and hypertrophy on the other, represent
two separate but interrelated processes. The former stimu-
lates reactions realized instantly, which are immediately
available, whereas the latter produces more gradually evolv-
ing reactions, which are of long-term adaptive benefit.
Immediate adaptation involves reactions for which the organ
has ready-made mechanisms in place. They include the
sudden increase in glycogenolysis and glucose oxidation in
response to a sudden increase in the work load of the heart
(23) and the switching from aerobic to anaerobic metabo-
lism in response to a lack of oxygen, with a resulting
accumulation of metabolic products. Long-term adaptation
involves reactions for which the heart possesses the genomic
prerequisites that allow the gradual evolution of adaptive
mechanisms in the face of repeated or persistent environ-
mental stimuli (24). For example, the adaptive responses to
training enable the organism to perform levels of physical
work not possible in the inherited untrained state. Likewise,
the heart’s adaptation to pressure overload prevents the
adaptive capacity of the organism from being exhausted
when environmental requirements are excessive or sustained
(25). Part of this adaptive process is a switch from fatty acids
to glucose as the main fuel for respiration, which would be
a beneficial adaptive response (26,27). This adaptive meta-
bolic response can precede any trophic changes (14) and
may, in its early phase, result in improved efficiency of the
heart.
Within this conceptual framework, it is easy to propose
that metabolic activity links gene expression with heart
function. Although the exact mechanisms of this link are
not yet completely understood, a growing body of evidence
indicates that the overall metabolic adaptations are brought
about, at least in part, by adjustments in the rate of
transcription of genes encoding proteins involved in energy
substrate metabolism (28).
Targeting metabolism to improve efficiency. As the study
by Wambolt et al. (1) shows, adaptation turns into malad-
aptation when an acute stress (ischemia and reperfusion) is
superimposed on an adaptive response. The excess produc-
tion of protons from enhanced glycolytic metabolism results
in contractile dysfunction by mechanisms that are not
completely understood. The deleterious effects on contrac-
tion that accompany enhanced glycolytic flux are prevented
by the addition of a drug that promotes pyruvate oxidation,
thereby reducing its conversion to lactate. Dichloroacetate,
like ranolazine, and probably also L-carnitine, activate the
pyruvate dehydrogenase (PDH) complex by inhibiting
pyruvate dehydrogenase kinase (PDK) (29–32). Restoring
carbon flux through PDH may be all that is necessary to
improve postischemic contractile function (30). Dichloro-
acetate, although not a specific inhibitor of PDK (33), is one
member of the growing group of drugs that target metab-
olism and metabolic efficiency in the normal, stressed,
ischemic or postischemic heart (34,35). These drugs include
propionyl L-carnitine (36), etomoxir (34), trimetazidine (37)
and troglitazone (38). Although acting at different sites, all
of them cause a pharmacologic switch from fatty acid to
glucose oxidation. Although it may have been possible to
predict the results of the present study, the work exposes an
important principle: Metabolic adaptation and maladapta-
tion of the heart are potential targets for pharmacotherapy.
Glucose is good for the heart as long as the heart can oxidize
glucose. In the future, this concept of intervening in altered
cellular metabolism may become as important as intervening
in altered blood supply through revascularization of the
ischemic heart.
However, this is not yet the time to rush to the pharmacy.
First, the observations were made in isolated perfused
hearts, and the systemic and toxic effects of the drugs may be
considerable. Second, dichloroacetate has been advocated as
a drug for the treatment of lactic acidosis (39) and conges-
tive heart failure (40). Yet, the effect of the drug is only
temporary and not sustained. Third, we still know far too
little about the inner workings of the heart. For example, in
the study by Wambolt et al. (1), proton production was only
calculated, and neither pH nor the redox state nor lactate
production was directly measured (refer to my earlier com-
ment on “lactate levels pending”). Because the control of
glycolytic flux is most likely distributed over several enzymes
in the pathway (41), and because enzymes may be regulated
by several allosteric and covalent regulators, we still do not
precisely know the mechanism by which glycolysis and
glucose oxidation are “out of step” in the hypertrophied and
reperfused heart. As Wambolt et al. discuss, direct measure-
ment of changes in intracellular pH, Na1 and Ca21
concentration would be necessary to support the conclu-
sions. Many more small steps are needed to master metab-
olism and to understand the interplay between gene regu-
lation and metabolic regulation of the heart. One example is
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the mitochondrial involvement in apoptosis (42,43), and the
metabolic regulation of this process (24). The message is
clear: Heart muscle has its own fuel economy that responds
to a wide spectrum of changes in its environment. More
importantly, drugs that improve ischemia tolerance, or
drugs that slow down programmed cell death, offer the
promise of targeted metabolic interventions, either in the
short term (by changing enzyme activities) or in the long
term (by alternating gene expression), in the heart. We may
be on our way to reclaim cardiology’s lost child.
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